MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients.
Applying our patented DNA methylation platform and biomarkers, we help address a large and growing unmet medical need for better cancer diagnosis and treatment information.
MDxHealth is a publicly-listed company trading on the NYSE Euronext (NYSE as in New York Stock Exchange) markets of Brussels and Amsterdam under the ticker symbol "MDXH".
MDxHealth (formerly OncoMethylome Sciences) was established in 2003 and is headquartered in Belgium. Its US headquarters is located in Irvine, CA.
MDxHealth develops molecular diagnostic products on its own or in partnership with pharmaceutical companies. Some of its products are already commercialized and the company has a broad pipeline of other products for major cancer indications.